Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01340755
Other study ID # 10-409
Secondary ID
Status Completed
Phase N/A
First received April 21, 2011
Last updated September 1, 2017
Start date March 2011
Est. completion date May 2017

Study information

Verified date September 2017
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transanal Endoscopic Rectosigmoid Resection with Laparoscopic Assistance was developed at Massachusetts General Hospital and performed successfully to remove cancer of the lower rectum. Based on the outcomes, the research doctors believe that this investigational surgery may be as safe and effective as standard laparoscopic or open surgery performed to remove rectal cancer, may facilitate the operation and reduce the size of the abdominal incisions. In this research study, the investigators are looking to see if this investigational procedure is a safe and effective approach to remove rectal cancer of the mid and lower rectum.


Description:

Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. At the end of the procedure, the rectum will be removed though the anus, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date May 2017
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Biopsy-proven adenocarcinoma of the rectum

- Eligible to undergo standard open or laparoscopic low anterior resection with a temporary diverting stoma

- Node negative (N0), T1 (high risk features), T2 and T3 rectal cancer on pelvic MRI

- Closest distance between tumor edge and mesorectal fascia 5mm or more based on pelvic MRI

- Rectal cancer located 4-12 cm from the anal verge

- ECOG performance status 2 or less

Exclusion Criteria:

- Metastasis

- Obstructing rectal cancer

- Synchronous colon cancer

- T3 rectal cancer not treated preoperatively with full-course chemoradiation

- Pregnant or breast-feeding

- Receiving any other study agents

- Fecal incontinence

- History of prior colorectal cancer

- History of inflammatory bowel disease

- History of pelvic radiation

- Prior pelvic surgery or multiple abdominal procedures

- BMI > 30

- Large uterine fibroids

- Uncontrolled intercurrent illness

- Other malignancies diagnosed within the previous year, except basal cell cancer

Study Design


Intervention

Procedure:
Transanal endoscopic surgery
Laparoscopy-assisted transanal endoscopic rectosigmoid resection

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Sylla P, Bordeianou LG, Berger D, Han KS, Lauwers GY, Sahani DV, Sbeih MA, Lacy AM, Rattner DW. A pilot study of natural orifice transanal endoscopic total mesorectal excision with laparoscopic assistance for rectal cancer. Surg Endosc. 2013 Sep;27(9):339 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens. 1-5 years
Secondary Incidence of 30-day perioperative complications including intraoperative, surgical postoperative, and medical postoperative complications. 1-5 years
Secondary Incidence of long-term complications 1-5 years
Secondary Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection 1-5 years
See also
  Status Clinical Trial Phase
Completed NCT00025337 - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Phase 3
Completed NCT03871959 - Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma Phase 1
Recruiting NCT05080673 - Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps N/A
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Completed NCT00551421 - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Phase 1/Phase 2
Terminated NCT00052585 - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer Phase 2
Completed NCT00023933 - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer Phase 1
Recruiting NCT03303547 - Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits N/A
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Terminated NCT00397878 - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer Phase 2
Completed NCT00100841 - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Recruiting NCT04005118 - Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
Completed NCT02641691 - Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum Phase 2
Completed NCT00307736 - Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer Phase 1/Phase 2
Completed NCT00003799 - Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer Phase 1
Terminated NCT00303628 - Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer Phase 3
Terminated NCT02425683 - Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX Phase 2
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1